A recent RCT showed that among adolescents with obesity, a once-weekly 2.4-mg dose of semaglutide, a GLP-1 RAs, combined with lifestyle intervention leads to a greater reduction in BMI, decreasing by 16.7% from baseline, compared to lifestyle intervention alone.64 The gene discussed is GLP1R; the disease is obesity disorder.